Genenta Science SPA

Genenta Science has a market capitalization of EUR 14.86 million, with a market price of EUR 0.63 per share, based on the latest available valuation data. The company has 23.59 million shares outstanding, with no dilution from potential share issuance, as the diluted and basic shares are equal. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company reported a loss per share of EUR 0.33 in the latest period, indicating a negative earnings performance. While no direct comparison to industry medians is available, the negative EPS suggests a lack of profitability, which is a concern for a company in the biotechnology and diagnostics space, where consistent revenue and profit generation are typically key to long-term viability.

Genenta Science's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the company's diversification or exposure to regional economic or regulatory risks. The absence of segmental or geographic breakdowns limits the ability to evaluate the company's strategic positioning or potential vulnerabilities.

The company's growth trajectory is unclear, as no forward-looking revenue guidance or historical growth rates are provided in the available data. The lack of disclosed growth metrics, combined with the current loss-making position, raises questions about the company's ability to scale or achieve profitability in the near term.

Risk factors include the inability to assess liquidity risk and the absence of going-concern language in source documents, which may indicate potential financial instability or operational challenges. The company is also at risk of dilution if it issues additional shares in the future, although no such plans are currently disclosed.

Recent events or filings have not been disclosed in the available data, so no specific developments can be reported at this time. The lack of recent disclosures may suggest limited transparency or a reduced level of investor communication.

Operating income −6,2% YoY; Net income −37,4% YoY.

• ▍Operating income −6,2% YoY
• ▍Net income −37,4% YoY
• ▍Free cash flow −36,7% YoY

Operating income −94,2% YoY; Net income −53,3% YoY.

• ▍Operating income −94,2% YoY
• ▍Net income −53,3% YoY
• ▍Free cash flow −53,6% YoY

Operating income -€5.7M.

• ▍Operating income -€5.7M